surf break copy_edited.jpg
surbreak-19.png
Search

xCures announces real-world biomarker study for patients with FGFR-mutant bladder cancer

Today, xCures announced their collaboration with Tyra Biosciences for a real-world biomarker study involving patients with FGFR-mutant bladder cancer receiving Balversa® (erdafitinib) as their standard of care medical therapy. The study is supported by Tyra Biosciences, Inc., a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. This study will investigate a patient’s tumor DNA through their blood and urine samples to provide information on their treatment and what options might be available if their disease worsens.


CONTINUE READING

Recent Posts

See All
WM360_logo-18.png